Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue
- PMID: 20039205
- PMCID: PMC2866528
- DOI: 10.1007/s10522-009-9259-6
Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue
Abstract
Fragile X syndrome afflicts 1 in 2,500 individuals and is the leading heritable cause of mental retardation worldwide. The overriding clinical manifestation of this disease is mild to severe cognitive impairment. Age-dependent cognitive decline has been identified in Fragile X patients, although it has not been fully characterized nor examined in animal models. A Drosophila model of this disease has been shown to display phenotypes bearing similarity to Fragile X symptoms. Most notably, we previously identified naive courtship and memory deficits in young adults with this model that appear to be due to enhanced metabotropic glutamate receptor (mGluR) signaling. Herein we have examined age-related cognitive decline in the Drosophila Fragile X model and found an age-dependent loss of learning during training. We demonstrate that treatment with mGluR antagonists or lithium can prevent this age-dependent cognitive impairment. We also show that treatment with mGluR antagonists or lithium during development alone displays differential efficacy in its ability to rescue naive courtship, learning during training and memory in aged flies. Furthermore, we show that continuous treatment during aging effectively rescues all of these phenotypes. These results indicate that the Drosophila model recapitulates the age-dependent cognitive decline observed in humans. This places Fragile X in a category with several other diseases that result in age-dependent cognitive decline. This demonstrates a role for the Drosophila Fragile X Mental Retardation Protein (dFMR1) in neuronal physiology with regard to cognition during the aging process. Our results indicate that misregulation of mGluR activity may be causative of this age onset decline and strengthens the possibility that mGluR antagonists and lithium may be potential pharmacologic compounds for counteracting several Fragile X symptoms.
Figures







Similar articles
-
Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.Neuron. 2005 Mar 3;45(5):753-64. doi: 10.1016/j.neuron.2005.01.038. Neuron. 2005. PMID: 15748850
-
PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.J Neurosci. 2015 Jan 7;35(1):396-408. doi: 10.1523/JNEUROSCI.1356-12.2015. J Neurosci. 2015. PMID: 25568131 Free PMC article.
-
Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model.Mol Psychiatry. 2017 Aug;22(8):1140-1148. doi: 10.1038/mp.2016.51. Epub 2016 Apr 19. Mol Psychiatry. 2017. PMID: 27090306 Free PMC article.
-
RNA interference: a new mechanism by which FMRP acts in the normal brain? What can Drosophila teach us?Ment Retard Dev Disabil Res Rev. 2004;10(1):68-74. doi: 10.1002/mrdd.20011. Ment Retard Dev Disabil Res Rev. 2004. PMID: 14994291 Review.
-
Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders.Genes (Basel). 2022 Dec 28;14(1):87. doi: 10.3390/genes14010087. Genes (Basel). 2022. PMID: 36672829 Free PMC article. Review.
Cited by
-
An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs.Nat Commun. 2024 Jul 8;15(1):5703. doi: 10.1038/s41467-024-50024-6. Nat Commun. 2024. PMID: 38977662 Free PMC article.
-
Drosophila melanogaster as a Model Organism to Study Lithium and Boron Bioactivity.Int J Mol Sci. 2021 Oct 28;22(21):11710. doi: 10.3390/ijms222111710. Int J Mol Sci. 2021. PMID: 34769143 Free PMC article. Review.
-
The challenges of clinical trials in fragile X syndrome.Psychopharmacology (Berl). 2014 Mar;231(6):1237-50. doi: 10.1007/s00213-013-3289-0. Epub 2013 Oct 31. Psychopharmacology (Berl). 2014. PMID: 24173622 Free PMC article. Review.
-
Molecular Biomarkers in Fragile X Syndrome.Brain Sci. 2019 Apr 27;9(5):96. doi: 10.3390/brainsci9050096. Brain Sci. 2019. PMID: 31035599 Free PMC article. Review.
-
Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome.Front Mol Neurosci. 2011 Nov 1;4:35. doi: 10.3389/fnmol.2011.00035. eCollection 2011. Front Mol Neurosci. 2011. PMID: 22053151 Free PMC article.
References
-
- Acharya JK, Labarca P, Delgado R, Jalink K, Zuker CS. Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. Neuron. 1998;20:1219–1229. - PubMed
-
- Bakker CE, Oostra BA. Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res. 2003;100:111–123. - PubMed
-
- Bastock MA. The courtship of drosophila melanogaster. Behaviour. 1955;8:86–111.
-
- Bastock MA. A gene mutation which changes a behavior pattern. Evolution. 1956;10:421–439.
-
- Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370–377. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases